Think.Health

Think.Health GmbH is a venture capital firm established in 2015 and headquartered in Fürstenfeldbruck, Germany, with an additional office in Berlin. The firm focuses on early-stage investments in the healthcare sector, including digital healthcare, medical technologies, diagnostics, biotechnology, and life sciences. Think.Health primarily targets companies in Germany, Austria, Switzerland, and the United States, preferring to invest between $0.24 million and $2.46 million. The firm aims to identify and support innovative and disruptive business models within healthcare ventures, making minority investments in seed-stage and early-stage companies.

Nils Bottler

Venture Partner

Dr. Florian Kainzinger

Managing Partner and Founder

Dr. Michael Ruoff

Partner

34 past transactions

Robeaute

Series A in 2025
Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

Inflammatix

Series E in 2024
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Sphingotec

Series C in 2024
Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

myo

Series A in 2024
Myo is a communication platform specifically designed for the elderly care sector. The company focuses on enhancing interactions among elderly individuals, their families, and caregivers by providing a user-friendly interface that incorporates traditional messaging features alongside transactional services. This platform facilitates the sharing of photos, videos, texts, and voice messages, allowing caregivers to communicate securely and professionally with relatives. Myo aims to improve the quality of care by fostering closer connections and enhancing communication within the care community. The company is also committed to expanding its team with talented individuals who are passionate about developing products that contribute to better care solutions.

Selfapy

Venture Round in 2023
Selfapy GmbH is a Berlin-based company that specializes in developing online therapy programs designed to assist individuals affected by mental health issues, particularly depression. Founded in 2016, Selfapy provides a range of therapy-related programs addressing anxiety, stress, eating disorders, and chronic panic, among others. The company’s offerings include three-month therapy solutions delivered via phone or SMS, featuring exercises, videos, and texts to guide users through their mental health journeys. By combining anonymity with flexibility, Selfapy aims to help users recognize negative thought patterns and develop healthier behaviors, all while having a personal psychologist as a companion in their self-help experience.

Navignostics

Seed Round in 2022
Navignostics is a biotechnology company focused on improving cancer treatment through advanced diagnostic techniques. By employing spatial single-cell proteomics, Navignostics characterizes tumors to identify the most effective treatment strategies for individual cancer patients. The company aims to reduce patient suffering by personalizing cancer therapies and ensuring that the right drug is available for each unique case. In addition to enhancing patient outcomes, Navignostics accelerates cancer drug development by offering valuable insights into drug mechanisms and tumor characteristics, which are essential for the creation of companion diagnostics. Their robust technology and data analytics capabilities position the company as a key player in precision cancer diagnostics, providing support to both patients and pharmaceutical partners in the fight against cancer.

Vara

Series A in 2022
Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

Anvajo

Series A in 2022
Anvajo is a developer of point-of-care technology focused on diagnostic testing of liquids. Originating from research at TU Dresden, the company has established a strong foundation in innovative research and successful product development, showcasing uninterrupted growth over several years. Anvajo has created a portable diagnostic device that integrates the key laboratory technologies of spectroscopy and microscopy, catering to diverse applications in human and veterinary medicine, as well as food, feed, environmental, and water analysis. This technology allows healthcare professionals to efficiently diagnose symptoms and diseases, streamlining the diagnostic process. In January 2020, the company relocated to a new 1,300 m² headquarters in Dresden, consolidating its development, production, and support functions under one roof to facilitate continued expansion and team development.

Inflammatix

Series D in 2021
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

myo

Series A in 2020
Myo is a communication platform specifically designed for the elderly care sector. The company focuses on enhancing interactions among elderly individuals, their families, and caregivers by providing a user-friendly interface that incorporates traditional messaging features alongside transactional services. This platform facilitates the sharing of photos, videos, texts, and voice messages, allowing caregivers to communicate securely and professionally with relatives. Myo aims to improve the quality of care by fostering closer connections and enhancing communication within the care community. The company is also committed to expanding its team with talented individuals who are passionate about developing products that contribute to better care solutions.

Vara

Series A in 2020
Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

Spindiag

Series B in 2020
SpinDiag GmbH is a German company specializing in the development of automated point-of-care systems for the rapid detection of infectious diseases. Founded in 2016 and headquartered in Freiburg, SpinDiag manufactures a compact, user-friendly centrifugal-microfluidic test system that enables healthcare professionals to detect drug-resistant bacteria and other pathogens directly from patient samples. Its flagship product, which includes an automated SARS-CoV-2 test, allows for the screening of up to 25 antibiotic resistances upon patient admission, effectively preventing the spread of infections by isolating affected individuals. The system streamlines the testing process with a fully automated workflow that can be operated by nursing staff, providing laboratory-grade PCR results from standard swab samples without the need for additional sample collection. By integrating this technology into everyday clinical practice, SpinDiag enhances diagnostic efficiency and safety in healthcare settings.

Endodont

Seed Round in 2020
Endodont GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing innovative products and processes for the dental industry. The company focuses on enhancing root canal treatments, offering solutions designed to improve root canal fillings through advanced technologies. Their product line includes features such as anti-leakage technology, inflammation-proof techniques, and denser filling materials that provide increased stability. These innovations aim to ensure safer and more efficient dental treatments, ultimately benefiting both patients and dental professionals by reducing treatment times and enhancing overall outcomes.

Selfapy

Series A in 2020
Selfapy GmbH is a Berlin-based company that specializes in developing online therapy programs designed to assist individuals affected by mental health issues, particularly depression. Founded in 2016, Selfapy provides a range of therapy-related programs addressing anxiety, stress, eating disorders, and chronic panic, among others. The company’s offerings include three-month therapy solutions delivered via phone or SMS, featuring exercises, videos, and texts to guide users through their mental health journeys. By combining anonymity with flexibility, Selfapy aims to help users recognize negative thought patterns and develop healthier behaviors, all while having a personal psychologist as a companion in their self-help experience.

Caspar

Series A in 2020
Caspar Health is a company focused on enhancing rehabilitation accessibility through its digital platform, which allows patients to receive care remotely after an illness or accident. The platform offers a variety of preconfigured therapy plans tailored to specific medical conditions, including movement exercises, seminars, and relaxation modules. This enables healthcare professionals to deliver effective and sustainable treatment regardless of the patient's location or time constraints. Recognized as a provider of tele-rehabilitation aftercare by the German Pension Fund, Caspar Health sets new standards in digital rehabilitation, promoting independence and recovery for individuals seeking to regain their quality of life.

Inflammatix

Series C in 2020
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Newsenselab (M-sense)

Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

First Light Diagnostics

Series A in 2019
First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Preomics

Series A in 2018
PreOmics GmbH is a biotechnology company based in Planegg, Germany, specializing in mass spectrometry (MS)-based proteomics. Founded in 2016 as a spin-off from the Max-Planck Institute of Biochemistry, PreOmics develops innovative tools and technologies aimed at enhancing protein analysis for researchers worldwide. The company's flagship product, the iST Kit, facilitates rapid and reproducible preparation of peptide mixtures from various starting materials, streamlining the sample preparation process within just one hour. PreOmics also offers high-throughput processing accessories and a robust platform that leverages liquid chromatography coupled with mass spectrometry to enable comprehensive protein identification, quantification, and analysis of post-translational modifications. Through its advanced solutions, PreOmics supports the scientific community in accelerating discovery and understanding of protein interactions and functions.

myo

Seed Round in 2018
Myo is a communication platform specifically designed for the elderly care sector. The company focuses on enhancing interactions among elderly individuals, their families, and caregivers by providing a user-friendly interface that incorporates traditional messaging features alongside transactional services. This platform facilitates the sharing of photos, videos, texts, and voice messages, allowing caregivers to communicate securely and professionally with relatives. Myo aims to improve the quality of care by fostering closer connections and enhancing communication within the care community. The company is also committed to expanding its team with talented individuals who are passionate about developing products that contribute to better care solutions.

Inflammatix

Series B in 2018
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Selfapy

Seed Round in 2018
Selfapy GmbH is a Berlin-based company that specializes in developing online therapy programs designed to assist individuals affected by mental health issues, particularly depression. Founded in 2016, Selfapy provides a range of therapy-related programs addressing anxiety, stress, eating disorders, and chronic panic, among others. The company’s offerings include three-month therapy solutions delivered via phone or SMS, featuring exercises, videos, and texts to guide users through their mental health journeys. By combining anonymity with flexibility, Selfapy aims to help users recognize negative thought patterns and develop healthier behaviors, all while having a personal psychologist as a companion in their self-help experience.

Newsenselab (M-sense)

Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Omnicare Pharma

Private Equity Round in 2017
Omnicare Pharma is a pharmaceutical wholesaler that specializes in the distribution of finished medicinal products to compounding pharmacies, particularly for the preparation of patient-specific cancer drugs. Operating within the realm of outpatient oncology care, the company supplies a nationwide network of pharmacies, facilitating efficient access to specialized medicines and services for oncological patients. By focusing on the needs of these patients, Omnicare Pharma aims to enhance the delivery of critical medical treatments and support the ongoing management of cancer care in outpatient settings.

Smarterials Technology

Seed Round in 2017
Smarterials Technology GmbH is a Berlin-based company that specializes in the design and development of advanced medical gloves and perforation indicators aimed at enhancing safety for healthcare professionals. Founded in 2016, Smarterials focuses on the creation of dual-barrier surgical gloves that provide superior protection against infection and injury. These innovative gloves feature a unique marker functionality that actively alerts physicians to potential perforations, thereby reducing the risk of contamination from infectious materials. By replacing traditional double-gloving methods, Smarterials' products not only help prevent infections but also contribute to cost savings and improved workflow efficiency in hospitals and care facilities.

Caspar

Seed Round in 2017
Caspar Health is a company focused on enhancing rehabilitation accessibility through its digital platform, which allows patients to receive care remotely after an illness or accident. The platform offers a variety of preconfigured therapy plans tailored to specific medical conditions, including movement exercises, seminars, and relaxation modules. This enables healthcare professionals to deliver effective and sustainable treatment regardless of the patient's location or time constraints. Recognized as a provider of tele-rehabilitation aftercare by the German Pension Fund, Caspar Health sets new standards in digital rehabilitation, promoting independence and recovery for individuals seeking to regain their quality of life.

Endodont

Seed Round in 2017
Endodont GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing innovative products and processes for the dental industry. The company focuses on enhancing root canal treatments, offering solutions designed to improve root canal fillings through advanced technologies. Their product line includes features such as anti-leakage technology, inflammation-proof techniques, and denser filling materials that provide increased stability. These innovations aim to ensure safer and more efficient dental treatments, ultimately benefiting both patients and dental professionals by reducing treatment times and enhancing overall outcomes.

Newsenselab (M-sense)

Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Hellocare

Seed Round in 2016
HelloCare is an online care and support marketplace that helps users find caregivers and domestic helpers in their cities. People can select the day, time, and the scope of services; receive a personal message with information on the representative or domestic helper assigned for them; visit the online profile of the candidate and see the reviews of other customers; and make payments via online tools to book the service. HelloCare enables independent caregivers and domestic workers to register as partners, access customer orders, and work without a direct boss.

Caspar

Seed Round in 2016
Caspar Health is a company focused on enhancing rehabilitation accessibility through its digital platform, which allows patients to receive care remotely after an illness or accident. The platform offers a variety of preconfigured therapy plans tailored to specific medical conditions, including movement exercises, seminars, and relaxation modules. This enables healthcare professionals to deliver effective and sustainable treatment regardless of the patient's location or time constraints. Recognized as a provider of tele-rehabilitation aftercare by the German Pension Fund, Caspar Health sets new standards in digital rehabilitation, promoting independence and recovery for individuals seeking to regain their quality of life.

Paula's Choice - Vẻ đẹp bắt đầu từ sự thật

Seed Round in 2016
HyHelp AG is a company based in Frankfurt am Main, Germany, that specializes in developing mobile devices and software tools for hygiene management in healthcare settings. Its innovative device is designed to assist healthcare professionals, including doctors and nurses, in enhancing hand hygiene practices, thereby reducing the incidence of nosocomial infections and improving overall patient safety. By enabling hospitals and other healthcare institutions to effectively track and monitor hand hygiene events, HyHelp plays a crucial role in promoting better hygiene standards within the medical community.

Paula's Choice - Vẻ đẹp bắt đầu từ sự thật

Seed Round in 2015
HyHelp AG is a company based in Frankfurt am Main, Germany, that specializes in developing mobile devices and software tools for hygiene management in healthcare settings. Its innovative device is designed to assist healthcare professionals, including doctors and nurses, in enhancing hand hygiene practices, thereby reducing the incidence of nosocomial infections and improving overall patient safety. By enabling hospitals and other healthcare institutions to effectively track and monitor hand hygiene events, HyHelp plays a crucial role in promoting better hygiene standards within the medical community.

Pedanios

Seed Round in 2015
Pedanios GmbH is a Berlin-based company specializing in the distribution of pharmaceutical products, with a particular focus on licensed narcotic drugs. Founded in 2015, Pedanios ensures high-quality medicines reach patients through rigorous selection of producers and extensive quality and safety measures. The company collaborates with specialized logistics partners for efficient product delivery. In December 2016, Cronos Group entered into an exclusive European supply agreement with Pedanios, designating Cronos as the sole North American supplier of cannabis products to Pedanios for distribution within the European Union.

Urban Sports Club

Seed Round in 2015
Urban Sports Club is a Berlin-based company founded in 2012 by Moritz Kreppel and Benjamin Roth, focused on promoting healthy and active lifestyles through a flexible sports membership model. It offers access to over 50 different sports activities, including gym workouts, swimming, yoga, and team sports, available at more than 10,000 partner venues across Germany, France, Italy, Spain, Portugal, and Belgium. The company targets both individuals and corporate clients, allowing members to enjoy a diverse range of wellness and fitness options. Following its initial bootstrapping phase, Urban Sports Club expanded through strategic acquisitions of several German competitors, including Somuchmore, FITrate, INTERFIT, and OneFit, enhancing its service offerings and market presence. The company's innovative approach aims to reinvent the leisure and corporate sports market by providing a comprehensive and convenient sports experience for its members.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.